J Korean Med Sci.  2004 Aug;19(4):514-518. 10.3346/jkms.2004.19.4.514.

Decreasing Incidence of Chronic Lung Disease Despite the Gradual Reduction of Postnatal Dexamethasone Use in Very Low Birth Weight Infants

• Choi CW
• Hwang JH
• Shim JW
• Ko SY
• Lee EK
• Kim SS
• Chang YS
• Park WS
• Shin SM

• KMID: 2157678
• DOI: http://doi.org/10.3346/jkms.2004.19.4.514

Abstract

Dexamethasone has been widely used in very low birth weight infants (VLBWI) weighing less than 1,500 g at birth for the prevention or treatment of chronic lung disease (CLD). Recently, however the use of dexamethasone is being reduced, as its association with abnormal neurodevelopmental outcome is known. On the other hand, there have been persistent concerns about the increased risk of CLD according to the reduction of postnatal dexamethasone use. Hence, we did a retrospective cohort study to delineate the change in the incidence of CLD according to the reduction of dexamethasone use in VLBWI. The medical records of 559 VLBWI admitted to neonatal intensive care unit at Samsung Medical Center between November 1994 and December 2002 were reviewed with a focus on the use of postnatal dexamethasone and the incidence of CLD. The use of postnatal dexamethasone has significantly decreased over the study period. Especially, the use of high-dose regimen has markedly decreased. The day when postnatal dexamethasone therapy was begun has also been significantly delayed. The incidence of CLD has significantly decreased over the same period. In conclusion, the incidence of CLD has not increased despite the decreased use of postnatal dexamethasone.

Keyword

Dexamethasone; Bronchopulmonary Dysplasia; Infant; Premature

MeSH Terms

Chronic Disease
Cohort Studies
Dexamethasone/*therapeutic use
Gestational Age
Humans
Infant
Infant, Newborn
*Infant, Very Low Birth Weight
Intensive Care Units, Neonatal
Lung Diseases/*drug therapy/*epidemiology
Male
Retrospective Studies

Reference

1. Mammel MC, Green TP, Johnson DE, Thompson TR. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet. 1983. 1:1356–1358.

2. Avery GB, Fletcher AB, Kaplan M, Brudno DS. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics. 1985. 75:106–111.

3. Grier DG, Halliday HL. Corticosteroids in the prevention and management of bronchopulmonary dysplasia. Semin Neonatol. 2003. 8:83–91.

4. Bhuta T, Ohlsson A. Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 1998. 79:F26–F33.

5. Arias-Camison JM, Lau J, Cole CH, Frantz ID 3rd. Meta-analysis of dexamethasone therapy started in the first 15 days of life for prevention of chronic lung disease in premature infants. Pediatr Pulmonol. 1999. 28:167–174.

6. Doyle L, Davis P. Postnatal corticosteroids in preterm infants: systematic review of effects on mortality and motor function. J Paediatr Child Health. 2000. 36:101–107.

7. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003. (1):CD001146.

8. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003. (1):CD001144.

9. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003. (1):CD001145.

10. Soll RF. for the Vermont Oxford Network Steroid Study Group. Early postnatal dexamethasone therapy for the prevention of chronic lung disease [abstract]. Pediatr Res. 1999. 42:123A.

11. Papile LA, Tyson JE, Stoll BJ, Wright LL, Donovan EF, Bauer CR, Krause-Steinrauf H, Verter J, Korones SB, Lemons JA, Fanaroff AA, Stevenson DK. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. N Engl J Med. 1998. 338:1112–1118.

12. Stoll BJ, Temprosa M, Tyson JE, Papile LA, Wright LL, Bauer CR, Donovan EF, Korones SB, Lemons JA, Fanaroff AA, Stevenson Dk, Oh W, Ehrenkranz RA, Shankaran S, Verter J. Dexamethasone therapy increases infection in very low birth weight infants. Pediatrics. 1999. 104:e63.

13. Ng PC, Blackburn ME, Brownlee KG, Buckler JM, Dear PR. Adrenal response in very low birthweight babies after dexamethasone treatment for bronchopulmonary dysplasia. Arch Dis Child. 1989. 64:1721–1726.

14. Leitch CA, Ahlrichs J, Karn C, Denne SC. Energy expenditure and energy intake during dexamethasone therapy for chronic lung disease. Pediatr Res. 1999. 46:109–113.

15. Berry MA, Abrahamowicz M, Usher RH. Factors associated with growth of extremely premature infants during initial hospitalization. Pediatrics. 1997. 100:640–646.

16. Yeh TF, Lin YJ, Huang CC, Chen YJ, Lin CH, Lin HC, Hsieh WS, Lien YJ. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics. 1998. 101:E7.

17. Vincer MJ, Allen AC. Double blind controlled trial of 6-day pulse of dexamethasone for very low birth weight infants (VLBWI <1,500 grams) who are ventilator dependent at weeks of age. Pediatr Res. 1998. 43:201A.

18. Kothadia JM, O'Shea TM, Roberts D, Auringer ST, Weaver RG III, Dillard RG. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants. Pediatrics. 1999. 104:22–27.

19. Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer S, Bader D, Yurman S, Dolfin T, Kogan A, Dollberg S, Arbel E, Goldberg M, Gur I, Naor N, Sirota L, Mogilner S, Zaritsky A, Barak M, Gottfried E. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed. 2000. 83:F177–F181.

20. Sharek PJ, Baker R, Litman F, Kaempf J, Burch K, Schwarz E, Sun S, Payne NR. Evaluation and development of potentially better practices to prevent chronic lung disease and reduce lung injury in neonates. Pediatrics. 2003. 111:e426–e431.

21. Burch K, Rhine W, Baker R, Litman F, Kaempf JW, Schwarz E, Sun S, Payne NR, Sharek PJ. Implementing potentially better practices to reduce lung injury in neonates. Pediatrics. 2003. 111:e432–e436.

22. Kaempf JW, Campbell B, Sklar RS, Arduza C, Gallegos R, Zabari M, Brown A, McDonald JV. Implementing potentially better practices to improve neonatal outcomes after reducing postnatal dexamethasone use in infants born between 501 and 1250 grams. Pediatrics. 2003. 111:e534–e541.

23. Jacobs HC, Chapman RL, Gross I. Premature conclusions on postnatal steroid effects. Pediatrics. 2002. 110:200–201.

24. Burchfield DJ. Postnatal steroids to treat or prevent chronic lung disease in preterm infants. Pediatrics. 2003. 110:221–222.

25. Volpe JJ. Neurology of the newborn. 2001. 4th Ed. Philadelphia: W.B. Saunders Co.;451.

26. Salafia CM, Weigl C, Silberman L. The prevalence and distribution of acute placental inflammation in uncomplicated term pregnancies. Obstet Gynecol. 1989. 73:383–389.

27. O'Shea TM, Kothadia JM, Klinepeter KL, Goldstein DJ, Jackson BG, Weaver RG 3rd, Dillard RG. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics. 1999. 104:15–21.

28. Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S, Donovan EF, Oh W, Bauer CR, Saha S, Poole WK, Stoll BJ. National Institute of Child Health and Human Development Neonatal Research Network. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med. 2001. 344:95–101.

29. Bell EF, Acarregui MJ. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2001. (3):CD000503.

30. Tammela OK, Koivisto ME. Fluid restriction for preventing bronchopulmonary dysplasia? Reduced fluid intake during the first weeks of life improves the outcome of low-birth-weight infants. Acta Paediatr. 1992. 81:207–212.

31. Davis P, Jankov R, Doyle L, Henschke P. Randomised, controlled trial of nasal continuous positive airway pressure in the extubation of infants weighing 600 to 1250 g. Arch Dis Child Fetal Neonatal Ed. 1998. 79:F54–F57.

32. So BH, Tamura M, Mishina J, Watanabe T, Kamoshita S. Application of nasal continuous positive airway pressure to early extubation in very low birthweight infants. Arch Dis Child Fetal Neonatal Ed. 1995. 72:F191–F193.

33. Tapia JL, Bancalari A, Gonzalez A, Mercado ME. Does continuous positive airway pressure (CPAP) during weaning from intermittent mandatory ventilation in very low birth weight infants have risks or benefits? A controlled trial. Pediatr Pulmonol. 1995. 19:269–274.

34. Rebello CM, Ikegami M, Polk DH, Jobe AH. Postnatal lung responses and surfactant function after fetal or maternal corticosteroid treatment. J Appl Physiol. 1996. 80:1674–1680.

35. Baud O, Foix-L'Helias L, Kaminski M, Audibert F, Jarreau PH, Papiernik E, Huon C, Lepercq J, Dehan M, Lacaze-Masmonteil T. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med. 1999. 341:1190–1196.

36. Shankaran S, Bauer CR, Bain R, Wright LL, Zachary J. Relationship between antenatal steroid administration and grades III and IV intracranial hemorrhage in low birth weight infants. The NICHD Neonatal Research Network. Am J Obstet Gynecol. 1995. 173:305–312.

37. LeFlore JL, Salhab WA, Broyles RS, Engle WD. Association of antenatal and postnatal dexamethasone exposure with outcomes in extremely low birth weight neonates. Pediatrics. 2002. 110:275–279.

38. Jobe AH, Wada N, Berry LM, Ikegami M, Ervin MG. Single and repetitive maternal glucocorticoid exposures reduce fetal growth in sheep. Am J Obstet Gynecol. 1998. 178:880–885.

39. Jobe AH, Newnham J, Willet K, Sly P, Ikegami M. Fetal versus maternal and gestational age effects of repetitive antenatal glucocorticoids. Pediatrics. 1998. 102:1116–1125.

40. Kim SH, Lee KH, You DK, Lee SH, Shim JW, Chang YS, et al. The incidence and risk factors of bronchopulmonary dysplasia (BPD) in very low birth weight infants. The 52nd Korean Pediatric Annual Meeting Abstract Book. 2002. 42.